Canadian status of "not acceptable" drugs as evaluated by Prescrire: A cohort study.

ABSTRACT:

Introduction

The independent French drug bulletin Prescrire International rates the therapeutic innovation of new drug-indications approved for marketing in France using an ordinal scale with the lowest rating being "not acceptable". This study investigates whether these drugs were approved by Health Canada.

Methods

A list of "not acceptable" drug-indications was generated by handsearching all issues of Prescrire International between January 2013 and December 2022. The generic names, indications and reasons why Prescrire labeled them not acceptable were recorded. The approval date was determined by consulting the website of the European Medicines Agency (EMA). The status of these drug-indications in Canada was determined by searching multiple Health Canada websites. Therape

SUBMITTER: Lexchin J 

PROVIDER: S-EPMC11293654 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature